Palla Pharma Limited announced that its applications to change the site of manufacture for its Co-Codamol tablet and caplet Marketing Authorisations to its Norway production facility have been granted by the UK medicines regulator (MHRA). This approval also includes the previously delayed approval of the Patient Information Leaflets and packaging of the products. All necessary approvals have now been granted and the first sales of these products are expected imminently. Initial batches of inventory in bulk tableted form have been produced and are on hand for immediate sale after packaging of the products has been completed. Production will now ramp up to meet actual and anticipated sales demand over the coming months. The process for supplying the Company's Co-Codamol products requires that intending purchasers be qualified as customers to meet quality and regulatory requirements. Several prospective customers have been qualified, with a further pipeline of indicative customer interest established in anticipation of the products shortly becoming available for sale. Market conditions remain attractive with continued product shortages in the UK. The Company has prioritised the manufacturing site change approval of the Co-Codamol products to target the UK's most significant market opportunity. Further submissions to the MHRA will be completed throughout 2021 for the remaining Marketing Authorisations acquired in 2020.